MDxHealth (MDXH) Q2 FY26 earnings call

MDxHealth delivered a strong rebound in Q2 FY26, marked by significant sequential revenue acceleration and the successful wind-down of its Resolve UTI business, eliminating a substantial contingent liability. The company is now solely focused on its urology market prostate cancer franchise, leveraging recent study publications and AI initiatives to drive future growth. Management reaffirmed full-year revenue guidance and expects to return to adjusted EBITDA profitability by year-end, supported by a strengthened balance sheet.